Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1996 1
1997 1
1998 1
1999 2
2001 2
2002 2
2003 1
2004 2
2005 2
2007 1
2010 3
2011 4
2012 3
2014 1
2016 1
2017 1
2018 2
2019 1
2022 1
2024 3
2025 0

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

33 results

Results by year

Filters applied: . Clear all
Page 1
Ocrelizumab versus Placebo in Primary Progressive Multiple Sclerosis.
Montalban X, Hauser SL, Kappos L, Arnold DL, Bar-Or A, Comi G, de Seze J, Giovannoni G, Hartung HP, Hemmer B, Lublin F, Rammohan KW, Selmaj K, Traboulsee A, Sauter A, Masterman D, Fontoura P, Belachew S, Garren H, Mairon N, Chin P, Wolinsky JS; ORATORIO Clinical Investigators. Montalban X, et al. N Engl J Med. 2017 Jan 19;376(3):209-220. doi: 10.1056/NEJMoa1606468. Epub 2016 Dec 21. N Engl J Med. 2017. PMID: 28002688 Free article. Clinical Trial.
A placebo-controlled trial of oral fingolimod in relapsing multiple sclerosis.
Kappos L, Radue EW, O'Connor P, Polman C, Hohlfeld R, Calabresi P, Selmaj K, Agoropoulou C, Leyk M, Zhang-Auberson L, Burtin P; FREEDOMS Study Group. Kappos L, et al. N Engl J Med. 2010 Feb 4;362(5):387-401. doi: 10.1056/NEJMoa0909494. Epub 2010 Jan 20. N Engl J Med. 2010. PMID: 20089952 Free article. Clinical Trial.
Comparison of switching to 6-week dosing of natalizumab versus continuing with 4-week dosing in patients with relapsing-remitting multiple sclerosis (NOVA): a randomised, controlled, open-label, phase 3b trial.
Foley JF, Defer G, Ryerson LZ, Cohen JA, Arnold DL, Butzkueven H, Cutter G, Giovannoni G, Killestein J, Wiendl H, Smirnakis K, Xiao S, Kong G, Kuhelj R, Campbell N; NOVA study investigators. Foley JF, et al. Lancet Neurol. 2022 Jul;21(7):608-619. doi: 10.1016/S1474-4422(22)00143-0. Epub 2022 Apr 25. Lancet Neurol. 2022. PMID: 35483387 Clinical Trial.
DISPEL: A Python Framework for Developing Measures From Digital Health Technologies.
Scotland A, Cosne G, Juraver A, Karatsidis A, Penalver-Andres J, Bartholome E, Kanzler CM, Mazza C, Roggen D, Hinchliffe C, Del Din S, Belachew S. Scotland A, et al. Among authors: bartholome e. IEEE Open J Eng Med Biol. 2024 May 17;5:494-497. doi: 10.1109/OJEMB.2024.3402531. eCollection 2024. IEEE Open J Eng Med Biol. 2024. PMID: 39050976 Free PMC article.
Effect of natalizumab on disease progression in secondary progressive multiple sclerosis (ASCEND): a phase 3, randomised, double-blind, placebo-controlled trial with an open-label extension.
Kapoor R, Ho PR, Campbell N, Chang I, Deykin A, Forrestal F, Lucas N, Yu B, Arnold DL, Freedman MS, Goldman MD, Hartung HP, Havrdová EK, Jeffery D, Miller A, Sellebjerg F, Cadavid D, Mikol D, Steiner D; ASCEND investigators. Kapoor R, et al. Lancet Neurol. 2018 May;17(5):405-415. doi: 10.1016/S1474-4422(18)30069-3. Epub 2018 Mar 12. Lancet Neurol. 2018. PMID: 29545067 Clinical Trial.
Sensor-Derived Measures of Motor and Cognitive Functions in People With Multiple Sclerosis Using Unsupervised Smartphone-Based Assessments: Proof-of-Concept Study.
Scaramozza M, Ruet A, Chiesa PA, Ahamada L, Bartholomé E, Carment L, Charre-Morin J, Cosne G, Diouf L, Guo CC, Juraver A, Kanzler CM, Karatsidis A, Mazzà C, Penalver-Andres J, Ruiz M, Saubusse A, Simoneau G, Scotland A, Sun Z, Tang M, van Beek J, Zajac L, Belachew S, Brochet B, Campbell N. Scaramozza M, et al. Among authors: bartholome e. JMIR Form Res. 2024 Nov 8;8:e60673. doi: 10.2196/60673. JMIR Form Res. 2024. PMID: 39515815 Free PMC article.
Konectom™ cognitive processing speed test enables reliable remote, unsupervised cognitive assessment in people with multiple sclerosis: Exploring the use of substitution time as a novel digital outcome measure.
Scaramozza M, Chiesa PA, Zajac L, Sun Z, Tang M, Juraver A, Bartholomé E, Charré-Morin J, Saubusse A, Johnson SC, Brochet B, Carment L, Ruiz M, Campbell N, Ruet A. Scaramozza M, et al. Among authors: bartholome e. Mult Scler. 2024 Aug;30(9):1193-1204. doi: 10.1177/13524585241259650. Epub 2024 Jun 24. Mult Scler. 2024. PMID: 38912764
33 results